| HOME >> MEDICINE >> TECHNOLOGY |
6.2 Clinical Trials by Phase 55
6.3 Clinical Trials by Trial Status 56
6.4 Clinical Trials by Overall Sponsors 57
6.5 Prominent Sponsors 58
6.6 Key Companies Participating in Therapeutics Clinical Trials 59
7 Chronic Heart Failure Therapeutics - Strategic Assessment 60
7.1 Key Events Impacting the Future Market 60
7.2 Chronic Heart Failure Therapeutics: Implications for Future Market Competition 61
8 Chronic Heart Failure Therapeutics - Future Players 62
8.1 Introduction 62
8.2 Company Profiles 63
8.2.1 Novartis AG. 63
8.2.2 Amgen Inc. 65
8.2.3 Cardiokine, Inc 66
8.2.4 Bayer AG. 67
8.2.5 Nile Therapeutics, Inc. 68
8.2.6 Cardioxyl Pharmaceuticals, Inc 69
8.2.7 Cytokinetics, Inc 70
8.2.8 GlaxoSmithKline plc 71
8.2.9 Trevena, Inc. 72
9 Chronic Heart Failure Therapeutics - Licensing and Partnership Deals 73
10 Chronic Heart Failure Therapeutics - Appendix 74
10.1 Market Definitions 74
10.2 Acronyms 74
10.3 Research Methodology 75
10.3.1 Coverage 76
10.3.2 Secondary Research 76
10.3.3 Forecasting 76
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 79
10.4 Contact Us 79
10.5 Disclaimer 79
10.6 Bibliography 80
List of Tables 1.1 List of TablesTable 1: Clinical Condition in Chronic Heart Failure 7
Table 2: Classification of Heart Failure by Structural Abnormality (ACC/AHA), or by Symptoms Relating to Functional Capacity (NYHA) 8
Table 3: Common Causes of Heart Failure due to Disease of Heart Muscle (Myocardial Disease) 8
Table 4: Cause and Precipitating Factor in Chronic Heart Failure 9
Table 5: Assessment of Congestion 10
Table 6: Common Electrocardiography Abnormalities in CHF 13
Table 7: Common Chest X-ray Abnormalities in Chronic Heart Failure 14
Table 8: Common Laboratory T
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |